Narcolepsy Type 2 with Excessive Daytime Sleepiness (No Cataplexy): When First-Line Wake-Promoting Therapy Has Not Achieved Adequate Control
This protocol applies to patients with narcolepsy type 2 whose excessive daytime sleepiness persists despite a structured first-line treatment attempt — and who require a defined next step.
Clinical scenario
Narcolepsy type 2 (NT2) is defined by excessive daytime sleepiness (EDS) in the absence of cataplexy. EDS is the hallmark symptom of narcolepsy; its absence distinguishes NT2 from narcolepsy type 1, which additionally involves cataplexy. This protocol is specific to NT2 patients whose daytime sleepiness has not been adequately managed.
Prior treatment — failure condition
A first-line, strongly recommended wake-promoting agent — modafinil, pitolisant, sodium oxybate, or solriamfetol — was trialled with the goals of reducing excessive daytime sleepiness and achieving an Epworth Sleepiness Scale score of no more than 10. This protocol is indicated when those goals were not reached.
Next-step approach (partial overview)
When first-line wake-promoting agents have not achieved adequate EDS control, a separate class of conditionally recommended agents — supported by low-to-moderate quality evidence — may be considered. The full structured protocol details which agents are appropriate and how they are applied.
References
- There are 2 primary classifications of narcolepsy, narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2).
- The hallmark symptom is excessive daytime sleepiness (EDS), but only patients with NT1 experience cataplexy.
- Other medications are conditionally recommended for EDS, including methylphenidate, dextroamphetamine, and armodafinil, generally as a result of low-to-moderate quality of evidence.
DOI: 10.9740/mhc.2025.12.258
View source ↗